Human bronchial air-liquid interface responses to nebulised protease exposure
Frontiers in Immunology · 07.08.2026 · 17
DOI: 10.3389/fimmu.2026.1875147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 07.08.2026. Verfasst von Georgina Hopkins und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, The University of Nottingham, Nottingham, United Kingdom. Hauptthemen laut MEDLINE: Bronchi, Peptide Hydrolases, Respiratory Mucosa, Epithelial Cells. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Background
As part of a programme developing human-relevant new approach methodologies (NAMs) for next-generation risk assessment (NGRA), we utilised a human air-liquid interface (ALI) bronchial epithelial model (MucilAir™) to assess epithelial responses to nebulised protease exposure.
Methods
Protease doses of 0.005, 0.08, 2, and 24 µg/cm 2 were applied to MucilAir™ inserts via nebulisation using a Vitrocell ® Cloud Alpha. Effects on epithelial barrier integrity, cytokine release, extracellular vesicle (EV) profiles, and EV transcriptomic cargo were evaluated.
Results
Phosphate-buffered saline (PBS) nebulisation produced no detectable barrier effects using the methods described. Protease doses of 2 µg/cm 2 or lower caused no significant responses compared with PBS controls. Protease doses of 24 µg/cm 2 induced reductions in TEER, GRO-α, IL-8/CXCL8, IL-9, and VEGF production, but increased MIF production, and EV alterations, indicating barrier disruption. Transcriptomic analysis of MucilAir™-derived EVs indicates a protease dose-dependent increase in differentially expressed microRNAs (miRNAs) that were enriched for pathways involved in epithelial signalling, immune and inflammatory regulation, cytoskeletal organisation, and cell survival and repair.
Discussion
These findings demonstrate the suitability of nebulised dosing for assessing airborne protease effects in bronchial ALI cultures. These data also highlight EV-miRNA profiling as a powerful, non-invasive readout that captures early molecular perturbations not detectable by conventional functional assays alone. Through identification of TEER, EV, and cytokine disruption thresholds to protease through statistical modelling, this work strengthens the methodological basis for generating NAM-aligned in vitro data to support risk assessment of inhaled enzymes and other airborne materials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, The University of Nottingham, Nottingham, United Kingdom.
- School of Medicine, Pharmacy, and Biosciences, Aston University, Birmingham, United Kingdom.
- Safety, Environmental and Regulatory Science, Unilever, Sharnbrook, Bedfordshire, United Kingdom.
- School of Veterinary Medicine and Science, The University of Nottingham, Nottingham, United Kingdom.
Förderung
- Wellcome Trust
Zitieren
APA
Hopkins, G., Sheffield, D., Barlow, H., Lalljie, A., James, V., Cochrane, S., & Fairclough, L. C. (2026). Human bronchial air-liquid interface responses to nebulised protease exposure. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1875147
Vancouver
Hopkins G, Sheffield D, Barlow H, Lalljie A, James V, Cochrane S, et al. Human bronchial air-liquid interface responses to nebulised protease exposure. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1875147
BibTeX
@article{Hopkins2026,
author = {Hopkins, Georgina and Sheffield, David and Barlow, Hugh and Lalljie, Anja and James, Victoria and Cochrane, Stella and Fairclough, Lucy C},
title = {Human bronchial air-liquid interface responses to nebulised protease exposure},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1875147}
}
EUVIMED